Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients ...

Dear K.T.: Dexfenfluramine, aka Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until ...

Dexfenfluramine, aka Redux (also called “fen-phen” in combination with phentermine), was sold in the 1990s until it was ...

Main pulmonary artery diameter is a prognostic indicator in patients with pulmonary arterial hypertension without congenital heart disease.

Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until it was removed from the market in 1997 after valvular heart damage and pulmonary hypertension were found.

Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension.

I took the diet drug Redux in the late 1990s. It was pulled off the market due to correlated heart issues. I saw a cardiologist and learned that I had mild to moderate mitral stenosis with ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

I took the diet drug Redux in the late 1990s. It was pulled off the market due to correlated heart issues. I saw a ...

Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...

Background: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely ...

The Eden Rose Foundation was founded in 2022 after Tyler and Molly Lockard of Worland, Wyo. lost their newborn Eden Rose ...